Brought to you by 
QLT, VasoGenix team up on delivery of CGPR
12 Apr 2005
Executive Summary
QLT USA (drug delivery) has agreed to help VasoGenix Pharmaceuticals (cardiovascular disease) develop a sustained-release formulation of its calcitonin gene related peptide (CGRP) with QLT's Atrigel biodegradable sustained-release drug delivery platform.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
QLT, VasoGenix team up on delivery of CGPR
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice